# A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

> **NCT07134842** · PHASE1 · RECRUITING · sponsor: **University College, London** · enrollment: 16 (estimated)

## Conditions studied

- Glioblastoma
- Gliosarcoma, Adult
- Glioblastoma - Category

## Interventions

- **BIOLOGICAL:** Ipilimumab (3 mg/kg)

## Key facts

- **NCT ID:** NCT07134842
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134842, "A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07134842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*